The New England Journal of Medicine (NEJM) RSS feed -- Search Results in Hematology/Oncology. NEJM (https://www.nejm.org) is a weekly general medical journal that publishes new medical research findings, review articles, and editorial opinion on a wide variety of topics of importance to biomedical science and clinical practice. https://www.nejm.org/action/showPodcastsFeeds NEJM Group Wed, 21 Oct 2026 22:08:10 GMT 2026 NEJM Group en-us 1440 Among patients with relapsed small-cell lung cancer after chemotherapy, treatment with tambotatug pelitecan led to longer survival than treatment with topotecan, with fewer adverse events of grade 3 or higher. https://www.nejm.org/doi/full/10.1056/NEJMoa2610229?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2610229 Yuanyuan Zhao, Hongxu Liu, Xiangjiao Meng, Zhihua Liu, Yan Yu, Yulong Zheng, Longhua Sun, Runxiang Yang, Jian Liu, Yanqiu Zhao, Lin Wu, Lei Yang, Zhiye Zhang, Mingjun Li, Peng Zhang, Yan Zhang, Hua Zhong, Jiuwei Cui, Zhangzhou Huang, Yanwei Yin, Manxiang Li, Fan Tong, Dan Xue, Dongqing Lv, Xufeng Li, Xian Zhang, Steve Chin, Jiaqiang Cai, Tongtong Xue, Yan Huang, Hongyun Zhao, Li Zhang, the TAISHAN-302 Investigators* 2026-10-22 Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy The discovery of H. pylori has advanced the prevention and treatment of gastritis, peptic ulcers, and gastric cancer. Progress has been made in the research of H. pylori infection. These advances are discussed in this review. https://www.nejm.org/doi/full/10.1056/NEJMra2414530?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMra2414530 Hong Li, Francis Megraud, Barry J. Marshall 2026-10-22 Helicobacter pylori Infection — Advances, Challenges, and the Road Ahead Kunihiro Hattori, Tomoyuki Igawa, and Takehisa Kitazawa, who developed a prophylactic therapy for hemophilia A, have received the 2026 Lasker–DeBakey Clinical Medical Research Award. https://www.nejm.org/doi/full/10.1056/NEJMcibr2608873?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMcibr2608873 Flora Peyvandi 2026-10-22 Reengineering Coagulation with a Bispecific Antibody A 52-year-old man with metastatic small-cell lung cancer was evaluated in the ophthalmology clinic because of vision loss in the left eye. A blood cytomegalovirus DNA viral load was 348 IU per milliliter. A diagnosis was made. https://www.nejm.org/doi/full/10.1056/NEJMcpc2603184?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMcpc2603184 Lucia Sobrin, K. Matthew McKay, Victor Kovac, Frances Wu, Anna M. Stagner 2026-10-22 Case 30-2026: A 52-Year-Old Man with Vision Loss in the Left Eye In a phase 1 study, RXRG001, a circular RNA encoding aquaporin-1, was administered to six patients with radiation-induced xerostomia. Measures of salivary flow improved, and adverse events were of grade 1 or 2 and transient. https://www.nejm.org/doi/full/10.1056/NEJMc2604891?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMc2604891 Henry T. Hoffman, Harry Quon, Christopher H. Rassekh, Hariz Hassan 2026-10-22 In Vivo Aquaporin-1 Circular RNA Therapy for Radiation-Induced Xerostomia In a trial involving adults with Ph-positive acute lymphoblastic leukemia, 24-month event-free survival was 86% with the TKI–immunotherapy combination ponatinib–blinatumomab and 67% with imatinib plus chemotherapy. https://www.nejm.org/doi/full/10.1056/NEJMoa2606208?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2606208 Sabina Chiaretti, Alfonso Piciocchi, Cristina Skert, Matteo Leoncin, Erika Borlenghi, Chiara Cattaneo, Mariangela Di Trani, Loredana Elia, Giada Almici, Deborah Cardinali, Francesca Kaiser, Federico Lussana, Paolo Fabio Fiumara, Cinzia Maugeri, Caterina Alati, Massimo Martino, Michela Ansuinelli, Giulia Lucco Navei, Daniele Mattei, Stefano Soddu, Monica Messina, Martina R. Marino, Valentina Mancini, Patrizia Chiusolo, Barbara Scappini, Maria P. Martelli, Prassede Salutari, Marco Cerrano, Bianca Serio, Antonella Cucca, Mario Luppi, Lara Pochintesta, Crescenza Pasciolla, Claudio Romani, Federico Mosna, Massimiliano Bonifacio, Ilaria Tanasi, Nicola S. Fracchiolla, Monica Bocchia, Silvia Imbergamo, Catello Califano, Giuseppe R. Nunziata, Mario Annunziata, Antonino Mulé, Patrizia Zappasodi, Sara Mastaglio, Sara Butera, Matteo G. Della Porta, Ferdinando Porretto, Monia Lunghi, Eleonora De Bellis, Elisabetta Todisco, Claudia M. Basilico, Paola Fazi, Alessandro Rambaldi, Renato Bassan, Robin Foà, the GIMEMA Investigators* 2026-10-15 Ponatinib–Blinatumomab or Imatinib–Chemotherapy for Adult Ph-Positive ALL In a phase 3, randomized trial of lonvo-z, an in vivo gene-editing therapy, patients with hereditary angioedema who received the drug had a significantly lower attack rate than those who received placebo. https://www.nejm.org/doi/full/10.1056/NEJMoa2600931?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2600931 Danny M. Cohn, Padmalal Gurugama, Hilary J. Longhurst, Emel Aygören-Pürsün, Timothy J. Craig, Henriette Farkas, Joshua Jacobs, William R. Lumry, Markus Magerl, Jonny Peter, Marc A. Riedl, David Maag, Adele Golden, Mrinal Y. Shah, Andrea Sutherland, Catherine R. Miller, Ahmed M. Abdelhady, Yuanxin Xu, James S. Butler, David Lebwohl, John Leonard, Aleena Banerji, the HAELO Investigators* 2026-10-15 Lonvoguran Ziclumeran — In Vivo CRISPR Gene Editing in Hereditary Angioedema A 39-year-old man, who was an Iraq War veteran with exposure to burn pits, was admitted to the hospital with hypertension, abdominal pain, and foot drop. Imaging showed a thoracic spinal mass. A diagnosis was made. https://www.nejm.org/doi/full/10.1056/NEJMcpc2603183?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMcpc2603183 Allan E. Pineda, Jad S. Husseini, Edwin Choy, Hugh G. Auchincloss, Ganesh M. Shankar, Frances J. Hayes, Valentina Zanfagnin 2026-10-15 Case 29-2026: A 39-Year-Old Man with Abdominal Pain, Foot Drop, and a Spinal Mass A 44-year-old man was admitted for the management of carcinoid syndrome, which had been diagnosed 4 years earlier. On examination, mottled, violaceous, blanchable flushing was seen across the face and torso. https://www.nejm.org/doi/full/10.1056/NEJMicm2606144?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMicm2606144 N. Karthik, Ashu Rastogi 2026-10-15 Flushing in Carcinoid Syndrome Hereditary angioedema is a disorder characterized by unpredictable, transient episodes of swelling and pain of various body parts. It can be life-threatening if the airway is involved. Current therapies include several different products that are administered prophylactically or at the onset of symptoms, and the prophylactic products must be administered... https://www.nejm.org/doi/full/10.1056/NEJMe2608188?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2608188 Peter Marks 2026-10-15 Adapting to Genomic Medicine The 21st volume of the IARC Handbooks summarizes and evaluates evidence for the benefits and harms of lung cancer screening with low-dose CT or chest radiography and assesses tools and strategies to improve screening. https://www.nejm.org/doi/full/10.1056/NEJMsb2608211?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMsb2608211 Luciana Neamtiu, Matthew E.J. Callister, Philip Crosbie, Stephen Lam, Vivienne Milch, Daniela Mariosa, Xiaoshuang Feng, Roya Dolatkhah, Ali Saeed Al-Zahrani, Zhandos Amankulov, Jean-Luc Bulliard, Wendy A. Cooper, Luis Corrales, Paolo Giorgi Rossi, Rayjean J. Hung, Ella Kazerooni, Mengmeng Li, Peter Mazzone, Rafael Meza, Arn Migowski, Rachael L. Murray, Samantha L. Quaife, Robert C. Rintoul, Witold Rzyman, Wei Jie Seow, Abhishek Shankar, Mahdi Sheikh, Hilary A. Robbins, Mattias Johansson, Harry J. de Koning, Béatrice Lauby-Secretan 2026-10-15 IARC Perspective on Lung Cancer Screening It would be rare for anyone who has undergone intensive, multicycle, multiagent chemotherapy followed by allogeneic hematopoietic stem-cell transplantation to agree with Nietzsche’s personal view that “Out of life’s school of war, what does not kill me, makes me stronger.” Even though our past approaches to treating patients with the... https://www.nejm.org/doi/full/10.1056/NEJMe2610489?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2610489 Adele K. Fielding 2026-10-15 Chemotherapy-free Treatment of Ph-Positive ALL In a trial of a blood-based multicancer early-detection test added to usual care, the incidence of stage III or IV cancer after three rounds of screening did not differ significantly from that with usual care alone. https://www.nejm.org/doi/full/10.1056/NEJMoa2505723?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2505723 Peter Sasieni, Peter Johnson, Thomas Round, Jane Warwick, Helen Jones, Saoirse Dolly, Lennard Lee, Yujin Lee, Harpal Kumar, Wei Liang, Rebecca Smittenaar, Richard D. Neal, Charles Swanton 2026-10-08 Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis This review summarizes advances in therapy, including approval or expanded use of targeted agents, improved outcomes with antibody–drug conjugates and immunotherapy, and growing reliance on molecular profiling. https://www.nejm.org/doi/full/10.1056/NEJMra2500695?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMra2500695 Sara Alsterlind Hurvitz 2026-10-08 Advances in Systemic Treatment of Breast Cancer A 19-year-old woman presented with fever and cervical lymphadenopathy. The white-cell count was 2900 per microliter (reference range, 4000 to 11,000), and the lactate dehydrogenase level was elevated. A diagnosis was made. https://www.nejm.org/doi/full/10.1056/NEJMcpc2603182?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMcpc2603182 Ezra M. Cohen, Shohei Fujita, Daniel R. Brown, Vanda F. Torous 2026-10-08 Case 28-2026: A 19-Year-Old Woman with Fever, Cervical Lymphadenopathy, and Leukopenia The diagnosis of cancer at earlier stages is generally associated with improved survival. Detecting circulating tumor–derived cell-free DNA (cfDNA) is an established method of monitoring the response to therapy for many cancer types, particularly hematopoietic and metastatic cancers — which leads to the question of whether screening for cfDNA in... https://www.nejm.org/doi/full/10.1056/NEJMe2611312?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2611312 David J. Hunter 2026-10-08 A Step in the Search for the Elusive Holy Grail of Early Detection of Cancer In ER-positive, HER2-negative advanced breast cancer, giredestrant, an ER degrader and full ER antagonist, plus everolimus led to longer progression-free survival than standard endocrine therapy–everolimus; safety was similar. https://www.nejm.org/doi/full/10.1056/NEJMoa2602457?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2602457 Erica L. Mayer, Sara M. Tolaney, Miguel Martín, Gregory A. Vidal, Luca Moscetti, Komal L. Jhaveri, Adam Brufsky, William J. Gradishar, Andreas Schneeweiss, Naoki Niikura, Anne Favret, Margarita Alfie, Keun Seok Lee, Sarah Khan, Merilin B. Feldman, Bann-mo Day, Lisa H. Lam, Walter C. Darbonne, Mona D. Shah, Kristin L. Griffiths, Gillian DiLallo, Pablo D. Pérez-Moreno, Hope S. Rugo, the evERA Breast Cancer Investigators* 2026-10-01 Giredestrant plus Everolimus in Advanced Breast Cancer A new European Union regulation introduces a centralized clinical assessment process for comparing the effectiveness and safety of new medicines with those of the standards of care in various countries. https://www.nejm.org/doi/full/10.1056/NEJMp2607902?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMp2607902 Huseyin Naci, Beate Wieseler 2026-10-01 Joint Clinical Assessments — A New Chapter in European Pharmaceutical Policy In a phase 1 study of anito-cel, a CAR T-cell therapy, for relapsed or refractory myeloma, all 38 patients had a response. Severe cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome were rare. https://www.nejm.org/doi/full/10.1056/NEJMoa2603527?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2603527 Matthew J. Frigault, Binod Dhakal, Andrzej J. Jakubowiak, Noopur Raje, Kamalika Banerjee, C. Jenny Mu, Kevin C. Hart, Sigal Shachar, Lawrence P. Andrews, Laurene S. Cheung, Faith M. Griffin, Alexandra R. Witter, Michael Hyde, Chester Pham, Nikitha Gandra, Tenzin Shakya, Bhargavi Rajan, Christa Cortesio, Samuel T. Haile, Heba Nowyhed, Priyanka Nair-Gupta, Priyam Mitra, Rebecca J. Chan, Ana Kostic, Christopher R. Heery, Jacalyn Rosenblatt, Michael R. Bishop 2026-09-24 Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma Persons with Wiskott–Aldrich syndrome were treated with an autologous gene therapy consisting of hematopoietic stem and progenitor cells transduced ex vivo with a lentiviral vector encoding WAS complementary DNA. https://www.nejm.org/doi/full/10.1056/NEJMoa2515005?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2515005 Francesca Ferrua, Sabina Cenciarelli, Stefania Giannelli, Stefania Galimberti, Shanmuganathan Chandrakasan, Federico Fraschetta, Carmen Caputo, Davide Sala, Ilaria Monti, Federica Barzaghi, Valeria Calbi, Daniele Canarutto, Giulia Consiglieri, Matteo Doglio, Francesca Fumagalli, Vera Gallo, Maddalena Migliavacca, Salvatore Recupero, Francesca Tucci, Alessia Orsini, Raffaella Milani, Mariam Datukishvili, Simona De Gregori, Eugenio Montini, Paolo Silvani, Matias Soncini, Elena Tomasetto, Koen van Rossem, Laura Castagnaro, Federica Miotto, Stefano Zancan, Celeste Scotti, Sean Russell, Luigi Naldini, Fabio Ciceri, Maria Ester Bernardo, Suhag Parikh, Maria Pia Cicalese, Alessandro Aiuti, the WAS Gene Therapy Group* 2026-09-24 Etuvetidigene Autotemcel for the Treatment of Wiskott–Aldrich Syndrome